Betrixaban Compared With Warfarin in Patients With Atrial Fibrillation: Results of a Phase 2, Randomized, Dose-Ranging Study (Explore-Xa)

Study Questions:

Betrixaban is a novel oral factor Xa inhibitor administered once daily, mostly excreted unchanged in the bile and with low (17%) renal excretion. What is the relative safety and tolerability of betrixaban at three different doses compared to dose-adjusted warfarin in patients with atrial fibrillation (AF) at risk of stroke?